| A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma (NCT05432219) | Eye & ENT Hospital of Fudan University | 2022-06-01 |
| Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC (NCT05350891) | Eye & ENT Hospital of Fudan University | 2022-05-08 |
| Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma (NCT05011227) | Eye & ENT Hospital of Fudan University | 2021-08-10 |
| Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT (NCT04215510) | Eye & ENT Hospital of Fudan University | 2021-03-01 |
| Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer (NCT04458909) | National Cancer Institute (NCI) | 2020-12-09 |
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer (NCT04231864) | Alain Algazi | 2020-12-01 |
| A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT04627961) | National University Hospital, Singapore | 2020-08-26 |
| Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy (NCT03689556) | Shanghai Proton and Heavy Ion Center | 2020-07-01 |
| Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma (NCT04425265) | Sun Yat-sen University | 2020-06-30 |
| Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma (NCT04376866) | Cancer Hospital of Guangxi Medical University | 2020-06-28 |
| Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. (NCT04405622) | Sun Yat-sen University | 2020-05-30 |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure (NCT04586088) | Sun Yat-sen University | 2020-05-05 |
| Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma (NCT03930498) | Sun Yat-sen University | 2020-03-12 |
| PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients (NCT03907826) | Sun Yat-sen University | 2020-03-01 |
| Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma (NCT03639467) | Chinese Academy of Medical Sciences | 2018-09-18 |
| A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. (NCT03210389) | Sun Yat-sen University | 2017-07-01 |
| Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) (NCT01392235) | Jiangsu HengRui Medicine Co., Ltd. | 2011-07-01 |
| MK-2206 in Recurrent Nasopharyngeal Carcinoma (NCT01370070) | Chinese University of Hong Kong | 2011-07-01 |